Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.31 USD
+0.02 (5.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.30 -0.01 (-1.93%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Dare Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 10 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 10 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 41 | 39 | 27 | 14 |
Income After Depreciation & Amortization | -31 | -31 | -39 | -27 | -14 |
Non-Operating Income | 1 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -31 | -39 | -27 | -14 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -31 | -39 | -27 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -31 | -39 | -27 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -31 | -39 | -27 | -14 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -31 | -31 | -39 | -27 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 87.30 | 84.57 | 61.15 | 30.09 | 15.58 |
Diluted EPS Before Non-Recurring Items | -0.35 | -0.37 | -0.63 | -0.91 | -0.97 |
Diluted Net EPS (GAAP) | -0.35 | -0.37 | -0.63 | -0.91 | -0.97 |
Fiscal Year end for Dare Bioscience, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.81 | 1.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 1.81 | 1.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 6.98 | 9.39 | 8.99 | 8.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.17 | -8.39 | -8.99 | -8.38 |
Non-Operating Income | NA | 0.11 | 0.10 | 0.23 | 0.34 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.06 | -8.30 | -8.76 | -8.04 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.06 | -8.30 | -8.76 | -8.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.06 | -8.30 | -8.76 | -8.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 84.29 | 91.05 | 86.40 | 85.52 |
Diluted EPS Before Non-Recurring Items | NA | -0.06 | -0.09 | -0.10 | -0.09 |
Diluted Net EPS (GAAP) | NA | -0.07 | -0.09 | -0.10 | -0.09 |